LON:SUMM Summit Therapeutics (SUMM) Share Forecast, Price & News GBX 20.50 0.00 (0.00%) (As of 02/21/2020) Add Compare Share Share Today's Range 18▼ 20.5050-Day Range 20.50▼ 20.5052-Week Range 18▼ 32.50Volume280,318 shsAverage Volume382,504 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesProfileChartCompetitorsHeadlines About Summit Therapeutics (LON:SUMM) StockSummit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.Read More SUMM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SUMM Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comCapstan Therapeutics to Participate in Upcoming Industry ConferencesSeptember 21, 2023 | finance.yahoo.comLeading Experts Join 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate CancerSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 20, 2023 | finance.yahoo.comSangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine SummitSeptember 18, 2023 | finance.yahoo.comAvalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF SummitSeptember 13, 2023 | finance.yahoo.comSling Therapeutics to Participate in the Stifel Virtual I&I SummitSeptember 8, 2023 | markets.businessinsider.comTravere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ LevelSeptember 7, 2023 | msn.comResolution on unified health architecture likely at summitSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 7, 2023 | businesswire.comCoya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted ...September 7, 2023 | businesswire.comVesigen Highlights New Data on Non-Viral Delivery Platform at the Exosome Based Therapeutic Development SummitSeptember 7, 2023 | finance.yahoo.comReCode Therapeutics to Present at September Investor ConferencesSeptember 6, 2023 | bizjournals.com$2M raise marks beginning of 'rapid' growth phase for this Santa Fe biotech startupAugust 31, 2023 | benzinga.comAkston Biosciences Receives 2023 Most Innovative Award at Animal Health SummitAugust 30, 2023 | finanznachrichten.deAkeso, Inc.: Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGFAugust 28, 2023 | finanznachrichten.deXNK Therapeutics AB: XNK Therapeutics to present at the 8th CAR-TCR Summit in BostonAugust 28, 2023 | finance.yahoo.comAbata Therapeutics to Present and Participate in Upcoming Investor and Industry EventsAugust 28, 2023 | benzinga.comXNK Therapeutics to present at the 8th CAR-TCR Summit in BostonAugust 24, 2023 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023August 22, 2023 | finance.yahoo.comMedigene AG to present at the 8th CAR-TCR Summit in BostonAugust 17, 2023 | finance.yahoo.comCytoMed Therapeutics Limited to Present at the August 24th Virtual Investor SummitAugust 16, 2023 | benzinga.comHalia Therapeutics Opens the Doors of its New Headquarters and Laboratory Facilities in Lehi, UtahAugust 11, 2023 | finanznachrichten.deTrevi Therapeutics, Inc.: Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business UpdateAugust 10, 2023 | msn.comMaxion Therapeutics moves into The Works on Unity CampusAugust 9, 2023 | msn.comSummit Therapeutics GAAP EPS of -$0.02August 3, 2023 | finance.yahoo.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJuly 25, 2023 | finance.yahoo.comCombined Therapeutics to Present Multi-Organ Protection (MOP) mRNA Vaccine Platform at the 3rd mRNA-Based Therapeutics SummitSee More Headlines Receive SUMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SUMM Company Calendar Last Earnings6/12/2019Today9/27/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:SUMM CUSIPN/A CIKN/A Webwww.summitplc.com Phone+44-1235-443939FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Glyn O. Edwards (Age 63)CEO & Exec. Director Mr. Erik Ostrowski (Age 46)Chief Financial Officer Prof. David Roblin (Age 53)COO, Chief Medical Officer and Pres of R&D Prof. Kay Davies (Age 69)Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Michelle AveryDirector of Investor RelationsKey CompetitorsAbzenaLON:ABZAAPR EnergyLON:APRCambian GroupLON:CMBNPremaitha HealthLON:NIPTSinclair PharmaLON:SPHView All Competitors SUMM Stock - Frequently Asked Questions How have SUMM shares performed in 2023? Summit Therapeutics' stock was trading at GBX 20.50 at the beginning of the year. Since then, SUMM stock has increased by 0.0% and is now trading at GBX 20.50. View the best growth stocks for 2023 here. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (LON:SUMM) posted its earnings results on Wednesday, June, 12th. The company reported ($3.00) EPS for the quarter, topping analysts' consensus estimates of ($4.00) by $1.00. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Diana Shipping (DSX), 2570 (JLF.L) (JLF), National Fuel Gas (NFG), Tailored Brands (TLRD), The Weir Group (WEIR) and Acacia Mining (ABGLF). What is Summit Therapeutics' stock symbol? Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM." How do I buy shares of Summit Therapeutics? Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Summit Therapeutics' stock price today? One share of SUMM stock can currently be purchased for approximately GBX 20.50. How can I contact Summit Therapeutics? Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The official website for the company is www.summitplc.com. The company can be reached via phone at +44-1235-443939. This page (LON:SUMM) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.